Parkinson's Parkinson's Complications and Comorbidities 2

Question 1

Parkinson's disease psychosis is currently treated with which FDA-approved antipsychotic that does not worsen motor symptoms?

Accepted Answer

Pimavanserin (Nuplazid)

Answer

Pimavanserin (Nuplazid) is the only FDA-approved treatment specifically for Parkinson's disease psychosis; it targets serotonin 5-HT2A receptors without blocking dopamine receptors, avoiding motor worsening.

Question 2

Excessive daytime sleepiness (EDS) in Parkinson's disease patients taking dopamine agonists is particularly dangerous because:

Accepted Answer

Patients can experience sudden sleep attacks while driving

Answer

Sudden onset sleep attacks associated with dopamine agonists in Parkinson's can occur without warning, creating a serious danger when driving or operating machinery.

Question 3

Camptocormia in Parkinson's disease refers to:

Accepted Answer

Severe forward flexion of the trunk

Answer

Camptocormia is an abnormal posture of severe forward trunk flexion (bent forward at the waist) seen in some Parkinson's patients due to axial muscle rigidity or dystonia.

Question 4

Which medication class is contraindicated in Parkinson's patients because it can dramatically worsen motor symptoms?

Accepted Answer

Dopamine-blocking antipsychotics (typical antipsychotics)

Answer

Typical antipsychotics (e.g., haloperidol, metoclopramide) block dopamine receptors and can severely worsen Parkinson's motor symptoms and should be avoided.

Question 5

Rapid eye movement (REM) sleep behavior disorder (RBD) in Parkinson's patients is associated with:

Accepted Answer

Higher risk of cognitive decline and dementia

Answer

The presence of RBD in Parkinson's disease is associated with greater disease burden, faster progression, higher risk of developing dementia, and more visual hallucinations.

Parkinson's Practice Test

Parkinson's Practice Test

Parkinson's Parkinson's Complications and Comorbidities 2